PLG0301 / Peptilogics - LARVOL DELTA

Peptilogics Receives Award from the Cystic Fibrosis Foundation to Investigate PLG0301 and PLG0206 as Potential Dual-Acting Treatments for Lung Infections Associated with Cystic Fibrosis (Businesswire) - "Peptilogics...today announced that the company received an award from the Cystic Fibrosis Foundation. The award will support preclinical research in a new class of engineered antibacterial peptides intended to serve as the first line of defense against invading pathogens, particularly bacteria, including multidrug resistant isolates that live in the airways of the lungs of cystic fibrosis (CF) patients and resist common antibiotic treatments....The preclinical research will focus on PLG0301 and PLG0206, two engineered cationic antibacterial peptides being developed by Peptilogics....The award provided by the Cystic Fibrosis Foundation will generate both in vitro and in vivo data about PLG0301 and PLG0206, which may potentially support an Investigational New Drug (IND) application with the FDA for its continued development."

Financing • Preclinical • Cystic Fibrosis